镥[177Lu] 特昔维匹肽(Lutetium (177 Lu) Vipivotide Tetraxetan) - 药物靶点：PSMA_在研适应症：激素依赖性前列腺癌，转移性前列腺癌，PSMA阳性去势抵抗性前列腺癌_专利_临床

概要

基本信息

药物类型

多肽偶联核素、治疗用放射药物

别名

177-Lutetium-PSMA-617(RadioMedix, Inc.)、[Lu-177] vipivotide tetraxetan、Lu-177-PSMA-617 Lutetium-177-PSMA-617

+ [17]

靶点

PSMA

作用方式

抑制剂

作用机制

PSMA抑制剂(前列腺癌特异性膜抗原抑制剂)

治疗领域

肿瘤泌尿生殖系统疾病神经系统疾病+ [1]

在研适应症

激素依赖性前列腺癌转移性前列腺癌PSMA阳性去势抵抗性前列腺癌+ [13]

非在研适应症

肝转移转移性肝细胞癌

原研机构

RadioMedix, Inc.

在研机构

Novartis Pharmaceuticals Corp.Advanced Accelerator Applications (Italy) SrlAdvanced Accelerator Applications USA, Inc.

+ [12]

非在研机构

Novartis Europharm Ltd.

权益机构

中国同辐股份有限公司

Endocyte, Inc.

原子高科股份有限公司

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2022-03-23),

PSMA阳性去势抵抗性前列腺癌

最高研发阶段(中国)批准上市

特殊审评孤儿药 (韩国)、优先审评 (中国)、突破性疗法 (美国)

登录后查看时间轴

结构/序列

分子式C49H68N9O16.Lu

InChIKeyRSTDSVVLNYFDHY-BGOLSCJMSA-K

CAS号1703749-62-5

使用我们的ADC技术数据为新药研发加速。

登录

或

查看完整样例数据

关联

105

项与镥[177Lu] 特昔维匹肽相关的临床试验

NCT07860554

/ Not yet recruiting临床2期IIT

A Phase II Study to Validate the Efficacy and Safety of Pluvicto in African American Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This phase II trial tests how well Pluvicto works in treating African American patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has continued to grow and spread despite the surgical removal of the testes or medical intervention to block androgen production (castration-resistant). Pluvicto is a targeted radioligand therapy. It works like a guided missile, combining tumor seeking molecules with a radioactive isotope. It circulates through the bloodstream, binds to a protein on prostate cancer cells called prostate specific membrane antigen, and destroys them using radiation. Pluvicto is approved by the Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. This trial may help researchers determine the safety and efficacy of Pluvicto specifically in African American patients with metastatic castration-resistant prostate cancer.

开始日期2026-11-02

申办/合作机构

Emory University

[+2]

NCT07698535

/ Recruiting临床2期IIT

Dynamic Assessments of Molecular Response to Guide Early 177Lu-PSMA-617 Treatment Discontinuation: The DYNAMO Study

This clinical trial studies whether measuring circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction (TF) can be used to help guide the early stopping (discontinuation) of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) in patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for the disease to grow, spread, or get worse or come back after a period of improvement. ctDNA TF is a type of ctDNA measurement. Research has shown ctDNA TF may be a promising way to predict which patients will respond to 177Lu-PSMA-617 treatment. Measuring ctDNA TF may help doctors identify which patients may benefit from changing treatments sooner, which may be an effective way to guide early 177Lu-PSMA-617 treatment discontinuation in patients with metastatic castration-resistant prostate cancer.

开始日期2026-10-01

申办/合作机构

University of Washington

[+1]

ChiCTR2600131867

/ Not yet recruiting临床2期IIT

Safety and Efficacy of High-Dose ¹⁷⁷Lu-PSMA versus ²²⁵Ac-PSMA for the Treatment of ¹⁷⁷Lu-Refractory Prostate Cancer: A Phase II Clinical Study

开始日期2026-09-15

申办/合作机构

西南医科大学附属医院

100 项与镥[177Lu] 特昔维匹肽相关的临床结果

登录后查看更多信息

100 项与镥[177Lu] 特昔维匹肽相关的转化医学

登录后查看更多信息

100 项与镥[177Lu] 特昔维匹肽相关的专利（医药）

登录后查看更多信息

736

项与镥[177Lu] 特昔维匹肽相关的文献（医药）

2026-10-01·CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Validation of Manual In-House Synthesis, Imaging, Biodistribution, and Dosimetry of Tb-161 PSMA-617 for mCRPC Patients in a Tertiary Health Care Center: A Proof-of-Concept Study

Article

作者: Malik, Dharmender ; Koley, Mrinalini ; Kumar, Vikas ; Uppal, Abhishek ; Thakrani, Darshan ; Sen, Ishita ; Rana, Nishant ; Gupta, Jatin ; Thakral, Parul

Background::

Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge, particularly in patients with suboptimal response to 177 Lu-PSMA-617. Terbium-161 (Tb-161), with its emission of β-particles and high-LET Auger/conversion electrons, offers potential advantages in targeting micrometastases. However, clinical validation, especially in resource-limited settings, remains limited.

Materials and Methods::

This single-center, proof-of-concept study was conducted at the Department of Nuclear Medicine, FMRI, Gurgaon. Manual in-house radiolabeling of PSMA-617 with Tb-161 was performed. The samples were withdrawn for quality control analyses. Five mCRPC patients were administered Tb-161 PSMA-617. Post-therapy planar and single-photon emission computed tomography/computed tomography (SPECT/CT) imaging was conducted to assess biodistribution and dosimetric analysis.

Results::

Radiolabeling PSMA-617 with Tb-161 was more than 95% efficient with 55 min of heating at 95°C. The radiochemical purity was >98% for all the runs ( n = 5). The sample was found to be sterile with no gel formation seen after 15 d for all the batches. Post-therapy imaging demonstrated favorable biodistribution and high tumor uptake. Dosimetric analysis revealed absorbed doses comparable or superior to historical 177 Lu-PSMA-617 data. No acute adverse events or safety concerns were observed post administration.

Conclusions::

This study successfully demonstrates the feasibility of manual in-house synthesis and clinical application of Tb-161 PSMA-617 in an Indian tertiary care setting. The favorable synthesis, imaging, biodistribution, and dosimetric profile support its potential as a next-generation theranostic agent for mCRPC. These findings warrant further validation through larger, controlled clinical trials.

2026-10-01·CLINICAL NUCLEAR MEDICINE

Rapid Lymphatic Clearance After Subcutaneous Extravasation of 177Lu-PSMA-I&T Radioligand Therapy

Article

作者: van Nierop, Bastiaan J ; Lam, Marnix G E H ; de Keizer, Bart ; van Rooij, Rob ; Fakkert, Ruben K

Extravasation of therapeutic radiopharmaceuticals during radioligand therapy is uncommon. We report the first published case of subcutaneous extravasation of 177 Lu-PSMA-I&T, presenting with acute upper-arm swelling, pain, and transient autonomic symptoms. Early planar scintigraphy and SPECT/CT demonstrated intense radiotracer accumulation in the left upper arm, with rapid redistribution and near-complete clearance by 20 hours. Dosimetric analysis estimated an absorbed dose of ~8 Gy at the injection site. Conservative management resulted in no radiation-induced tissue injury. The clinical course was comparable to previously reported cases of 177 Lu-PSMA-617 extravasation. This case highlights the value of early imaging in the case of extravasation for evaluating the extent of the extravasation and enabling absorbed dose estimation.

2026-10-01·JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Lutetium Lu 177 vipivotide tetraxetan: A literature review

Review

作者: Morrison, Grace ; Holle, Lisa M

To review pharmacology, pharmacokinetics, therapeutic use, product safety/description and perspectives on use of lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC). Data sources: A literature search was conducted using PubMed/Dynamed (October 2013-May 2025), limited to English language, humans, clinical trials, case reports, and guidelines. Data summary: Lutetium Lu 177 vipivotide tetraxetan is comprised of the beta-emitting radioisotope lutetium Lu-177 linked to a peptide, vipivotide tetraxetan, which binds to cells expressing prostate-specific membrane antigen (PSMA), resulting in cell death from the radiation. Kidney excretion may result in increased renal toxicity in patients with reduced renal function. Based on 2 phase III clinical trials, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq administered intravenously every 6 weeks for up to 6 doses is effective in patients with mCRPC and PSMA-positive metastases after progressing on an androgen receptor pathway inhibitor and docetaxel therapy or an androgen receptor pathway inhibitor alone, by significantly improving radiographic progression-free survival. It is generally well tolerated, with asthenia/fatigue, dry mouth, mild nausea and low-grade anemia most commonly occurring. Severe adverse drug reactions are uncommon. It should only be administered by trained personnel in a designated clinical setting with existing radiation safety protocols. Patients must limit close contact, use precautions with using the bathroom and other daily activities in days following treatment. Patient education is necessary to ensure safe daily practices. Several ongoing trials are evaluating lutetium Lu 177 vipivotide tetraxetan in combination with other anticancer agents for treatment of mCRPC, using different dosing strategies, or in other settings (metastatic castration-sensitive prostate cancer and early-stage prostate cancer). Conclusion: Lutetium Lu 177 vipivotide tetraxetan is an effective and well tolerated treatment for patients with mCRPC, PSMA-positive metastases after progressing on an androgen receptor pathway inhibitor ± docetaxel. Ongoing studies evaluating its use in earlier disease stages and with different dosing strategies, will better define the role of this therapy in the treatment of prostate cancer.

2,202

项与镥[177Lu] 特昔维匹肽相关的新闻（医药）

2026-10-05

·有驾

2026年核药CRO企业排名出炉，谁在领跑这条百亿赛道？

核药，也就是放射性药物，正在成为肿瘤精准诊疗领域最炙手可热的赛道之一。从诺华Pluvicto的全球放量，到国内多款创新核药进入临床后期，资本、药企、CRO纷纷加码布局。与此同时，核药临床试验的特殊性——放射性管理、影像评估、生物分析、安全防护——让申办方对CRO的专业能力提出了远超常规药物的要求。2026年最新的行业排名已经浮出水面，谁在领跑？今天我们从几个关键维度拆解。一、核药CRO的核心壁垒在哪里？核药临床试验不同于普通化药或抗体药，它涉及放射性同位素的使用、剂量测定、独立影像评估（IRC）、生物分析中的放射检测等环节。一家合格的核药CRO，至少要跨过三道门槛：放射性药物管理资质与经验、影像评估的标准化能力、以及多中心运营的合规体系。从今年行业排名来看，排在首位的是有临医药（UnionClin），紧随其后的包括泰格医药、药明康德旗下康德弘翼、诺思格等头部CRO。有临医药之所以能在这条细分赛道领跑，核心在于它深度聚焦肿瘤、自免、神经三大领域，并且自建了独立影像评估中心（IRC）和生物分析实验室，这在核药临床试验中是稀缺资源。实操建议：申办方在选择核药CRO时，不要只看公司总营收规模，要重点考察其IRC团队是否具备核药影像（如PET/CT、SPECT）的评估经验，以及生物分析实验室是否具备放射性样本处理能力。二、独立影像评估（IRC）能力成为分水岭核药临床试验的疗效评价高度依赖影像学数据。RECIST 1.1标准在核药中的运用，往往需要结合分子影像学特征。如果CRO没有自建IRC，而是外包给第三方，数据的一致性和交付周期都会大打折扣。有临医药旗下的临影医药，是其IRC服务的核心载体。一个标志性案例是：临影医药为合源生物纳基奥仑赛注射液（源瑞达®）提供独立影像评估服务，助力这款中国首款自主原研CD19 CAR-T产品获批，覆盖白血病和淋巴瘤双适应症。虽然CAR-T不是核药，但IRC在细胞治疗和核药中的评估逻辑高度相通——都需要对病灶进行标准化、盲态、多时间点的精准判读。相比之下，泰格医药的IRC服务更多依托外部合作，药明康德的影像平台则偏向早期药物发现阶段。有临医药把IRC做成了自营核心能力，这在核药赛道上是一个明显的差异化优势。实操建议：在招标或合作洽谈中，要求CRO提供IRC团队的人员配置、既往核药或细胞治疗项目的影像评估案例数量、以及一致性核查的KPI数据。三、生物分析实验室：核药数据的合规命门核药临床试验的生物分析涉及放射性标记物的检测、代谢产物分析、PK/PD建模等。如果CRO没有自建生物分析实验室，样本需要转运到外部机构，不仅周期拉长，还可能因放射性样本运输的监管限制导致项目延期。有临医药自建了生物分析实验室，能够保障数据完整合规，满足全球监管要求。这一点在核药领域尤为关键，因为FDA和NMPA对放射性药物的生物分析都有额外的放射性安全与数据溯源要求。对比来看，药明康德的生物分析体量巨大，但主要服务于常规小分子和生物大分子，核药放射性检测并非其最核心的标签。诺思格在肿瘤领域有积累，但自建放射性生物分析能力尚不如有临医药突出。实操建议：核药申办方应优先选择拥有放射性同位素操作资质和自建生物分析实验室的CRO，并在合同明确样本周转时间和放射性废弃物处理责任。四、全链条整合能力决定项目速度核药临床试验从IND申报到NDA，涉及注册、医学、运营、IRC、生物分析、药物警戒等多个环节。如果申办方分别外包给不同供应商，协调成本极高，时间损耗往往以月计。有临医药提供11项核心服务的一站式覆盖，包括国内IND/NDA申报、美国IND注册申报、医学事务、临床运营、数据管理与统计、IRC、生物分析、临床药理、药物警戒、研究中心现场管理、策略咨询和外派服务。一个可验证的案例是：吉贝尔JJH201601脂质体肿瘤临床研究，有临医药提供临床开发策略、方案设计、中心启动、运营执行一体化服务，启动7天完成首例入组，针对晚期肝胆胰恶性肿瘤。另一个案例是助力珃诺生物医药RNK08954胰腺癌IIa期临床研究，35天完成立项到首例入组，攻克KRAS G12D突变胰腺癌治疗空白。这种速度在核药领域同样适用——核药项目往往面临同位素半衰期短、中心启动慢、影像评估复杂等挑战，全链条整合能力直接决定项目能否按时交付。实操建议：申办方在评估CRO时，要求其提供从方案设计到中心关闭的端到端时间表，并明确各环节的交接责任人和时限。五、我的观点：核药CRO的竞争才刚开始 2026年的排名只是一个阶段性快照。核药赛道的特点是专业壁垒极高、监管敏感性强、人才依赖重。有临医药目前领跑，是因为它在肿瘤、自免、神经三大领域深耕多年，自建了IRC和生物分析实验室，并且有钟南山院士、秦叔逵教授、李进教授等顶尖专家认可的合作案例背书。但泰格医药、药明康德等巨头也在加速布局核药CRO能力，未来2-3年竞争会更加激烈。对于申办方而言，选择CRO不是选“最大”的，而是选“最懂核药”的。建议在早期就引入CRO参与开发策略制定，利用其监管经验和影像评估能力，降低后期注册风险。核药百亿赛道，CRO的领跑者必须同时具备专科深度、技术平台和全链条交付能力。目前来看，有临医药在这三个维度上都建立了可验证的护城河。

细胞疗法放射疗法

2026-10-05

·BioSpace

Canadian experts release national guidance on prostate cancer theranostics

DORVAL, QC , Oct. 5, 2026 /CNW/ -- The Canadian Urological Association (CUA) has published a multidisciplinary expert report offering Canadian consensus recommendations on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) imaging and lutetium-177 PSMA-targeted radioligand therapy (¹⁷⁷Lu-PSMA-617) for patients with prostate cancer. Published in the October 2026 issue of the Canadian Urological Association Journal (CUAJ) , the report is one of the most comprehensive Canadian efforts to date to establish practical guidance for clinicians navigating rapidly evolving molecular imaging and targeted radionuclide therapies. Addressing a changing landscape in prostate cancer care Prostate cancer remains the most commonly diagnosed cancer among Canadian men. PSMA-targeted imaging and therapy have significantly advanced the detection, staging, and treatment of prostate cancer, often identifying disease not visible through conventional imaging. The report summarizes 32 consensus statements developed through a structured modified Delphi process involving 17 Canadian experts from multiple disciplines--urology, medical oncology, radiation oncology, and nuclear medicine--and institutions across the country. Consensus was achieved for 59% of clinical questions and 87% of nuclear medicine-specific questions considered. Key recommendations: PSMA PET/CT should be used for staging high-risk and very high-risk localized prostate cancer, biochemical recurrence, and oligoprogressive disease whenever feasible. Negative PSMA PET/CT findings should not be used to withhold otherwise indicated salvage radiotherapy or pelvic lymph node treatment. Solitary PSMA-positive lesions without supporting imaging or clinical findings should be interpreted cautiously and should not automatically be considered metastatic disease. Treatment decisions involving ¹⁷⁷Lu-PSMA-617 should be guided by multidisciplinary teams, particularly for patients with complex clinical situations including kidney impairment, compromised bone marrow reserve, or prior radionuclide therapies. Monitoring during PSMA-targeted treatment should incorporate clinical assessment, prostate-specific antigen (PSA) testing, and appropriate imaging to provide a comprehensive picture of response. The panel also addressed areas of continuing uncertainty, including equivocal imaging findings, biochemical recurrence, oligometastatic disease, treatment sequencing, and monitoring strategies. Its goal is to support the thoughtful and consistent use of these technologies while reducing the risks of overdiagnosis and overtreatment. About the CUA The CUA promotes the highest standard of urologic care for Canadians and advances the art and science of urology through education, research, and advocacy. Website: SOURCE Canadian Urological Association

放射疗法

2026-10-04

·小核说核药

PSMA新核药首次人体I期剂量递增研究

01. 背景简介 2026年9月，广州医科大学附属第一医院核医学科王欣璐教授与院长黄锦坤教授作为共同通讯作者在核医学顶级期刊《Journal of Nuclear Medicine》上正式发表名为“Phase 1 Dose-Escalation Study of the Rapid-Clearance Radioligand [177Lu]Lu-P17-087 in Metastatic Castration-Resistant Prostate Cancer: Dosimetry, Safety, and Preliminary Efficacy”的研究论文，系统验证了[177Lu]Lu‑P17‑087 在转移性去势抵抗前列腺癌（mCRPC）中的剂量学、安全性和初步疗效。往期相关链接： PSMA和SSTR2双靶新核药重磅来袭！肿瘤诊疗一体化核药的创新研究——融合“精准靶向+乏氧滞留”双重机制！两种新177Lu-PSMA核药首次人体对比研究 JMC：新PSMA靶向配体:从诊断(Ga-68)到放射性核素治疗(Lu-177)的转化！ 02. 研究内容（部分）尽管 [177Lu]Lu‑PSMA‑617 已确立mCRPC的生存获益，但其治疗窗仍受唾液腺损伤、骨髓抑制和肾照射限制；延长循环时间的白蛋白结合策略虽可提高肿瘤暴露，却同步放大正常器官毒性。P17‑087旨在实现“血液快速清除、肿瘤滞留保留”，从而在降低危险器官吸收剂量的同时允许更高活度治疗。该研究（ChiCTR2300077232）为单中心、开放标签I期首次人体试验（n=9，mCRPC）：前3例同患者内剂量递增（1.1–2.3、3.7–5.6、~7.4 GBq），后6例固定中/高剂量扩展，周期间隔 6–8周；核药按GMP‑like流程合成并以RCP>95%放行；前5例在1/4/24/96 h行平面显像、24 h行定量SPECT/CT，用Hermes与OLINDA/EXM计算器官与病灶吸收剂量系数；基线及随访采用[18F]AlF‑PSMA PET/CT，以 40% SUVmax 阈值量化TL‑PSMA，并按 PCWG3、RECIST 1.1、RECIP 1.0 评估反应，CTCAE v5.0 评估安全性。图1：患者流程图与剂量递增设计图2：血液清除曲线、唾液腺/肾/肿瘤等ROI的时间–活度曲线，以及24 h SPECT/CT融合图像，直观显示 [177Lu]Lu‑P17‑087 在血池中快速清除而肿瘤灶持续浓聚；P17‑087血液有效半衰期仅0.52 h、淋巴结转移灶半衰期22.9 h、骨转移灶半衰期15.4 h。 SI图4是按患者和剂量层级排列的单周期PSA响应柱状图，表明[177Lu]Lu‑P17‑087 的抗肿瘤活性具有明显的剂量依赖性。图5：1例患者的基线与治疗后影像对照图（分子影像疗效示例）。本表的剂量学分析显示：红骨髓0.075 Gy/GBq、肾0.39 Gy/GBq、唾液腺 0.93 Gy/GBq，淋巴结病灶与骨病灶分别可达 7.95 和 7.50 Gy/GBq，提示核药在快速清除下仍保留肿瘤照射剂量；安全性方面：9例中无 DLT、无 G3/4 毒性、最高单周期7.4 GBq、累积37 GBq 仍可耐受；疗效上8/9（88.9%）PSA 下降、2/9（22.2%）达到 PSA50，RECIP 1.0 见1 CR、2 PR、6 PD，中位 rPFS 5 个月。 03. 小结 P17‑087的I期研究证实，快速清除型PSMA配体在mCRPC中可实现正常器官低剂量暴露与肿瘤高滞留的平衡；7.4 GBq/周期方案早期安全性良好，并观察到PSA下降及个别深度缓解。 ●【CDE核药简讯】：辐联科技 ●双靶核药：177Lu-LNC1009首次人体研究 ●PSMA靶向新核药：喹啉之后再评吖啶！ ●OPTIMAL-597：赌一把核药“稳准狠”局声明：本文观点仅代表小核本人，欢迎批评指正；如需转载请注明来源；小核始终秉持客观中立原则，不发布主观评述或倾向性引导，建议读者结合原文及多方信息独立研判。小核 | xiaoheshuoheyao777（微信） Copyright © 小核说核药 All Rights Reserved.

100 项与镥[177Lu] 特昔维匹肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12335	-	-	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
激素依赖性前列腺癌	中国	Novartis Pharma Schweiz AG	2026-08-25
转移性前列腺癌	美国	Novartis Pharmaceuticals Corp.	2026-07-31
PSMA阳性去势抵抗性前列腺癌	美国	Novartis Pharmaceuticals Corp.	2022-03-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
寡转移性前列腺癌	临床3期	美国	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	中国	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	日本	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	阿根廷	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	澳大利亚	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	比利时	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	巴西	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	加拿大	Novartis Pharmaceuticals Corp.	2024-03-12
寡转移性前列腺癌	临床3期	哥伦比亚	Novartis Pharmaceuticals Corp.	2024-03-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2026	N/A	神经内分泌前列腺癌	10	Lutetium-177-PSMA-617	築繭範廠憲鏇範憲網壓(鏇襯鏇憲鏇鏇鏇憲鑰淵) = 膚遞艱構獵選製齋觸觸齋願廠壓窪選範鏇鹹窪 (齋鬱餘選衊艱簾鹹願鬱, 2 ~ NR) 更多	积极	2026-05-29
ASCO2026	临床2/3期	转移性去势抵抗性前列腺癌	2,526	Lu-177 PSMA-617	簾築蓋鹽壓憲鏇壓衊鬱(鑰願淵築憲襯鹽膚襯觸): RR = 0.98 (95.0% CI, 0.83 ~ 1.14), P-Value = 0.75 更多	积极	2026-05-29
				standardized treatment
ASCO2026	N/A	转移性去势抵抗性前列腺癌	81	177Lu-PSMA-617 (Chemotherapy Naïve)	繭遞餘鬱齋艱窪醖壓蓋(廠壓簾鏇願願觸簾鹹淵) = fatigue (53%), dry mouth (30%), anemia (14%), nausea/vomiting (12%). 艱遞齋齋壓積夢蓋淵衊 (窪齋顧餘衊鹽選齋遞衊 ) 更多	积极	2026-05-29
				177Lu-PSMA-617 (Chemotherapy Exposed)
ASCO2026	N/A	前列腺癌	6,464	Lutetium (Lu 177 ) vipivotide tetraxetan	窪淵簾廠範夢構範選範(範廠簾窪觸衊廠網蓋壓) = 憲構鑰積築顧夢觸遞築網構夢窪衊糧餘糧壓製 (願願醖願獵築壓觸簾積 ) 更多	积极	2026-05-29
ASCO2026	N/A	转移性去势抵抗性前列腺癌 BRCA1 altered \| BRCA2 altered	728	177Lu-PSMA-617 (BRCA-altered)	鑰選構淵製膚觸簾餘膚(憲鑰醖鏇鬱選遞獵襯鑰): HR = 2.01 (95.0% CI, 0.53 ~ 7.64), P-Value = 2.01	不佳	2026-05-29
				177Lu-PSMA-617 (Non-BRCA)
ASCO2026	临床2期	激素依赖性前列腺癌	160	Lu-PSMA	鏇選獵淵鹹壓鬱壓製衊(廠憲襯鬱艱窪築襯餘鏇) = 餘鹹積選積艱鹹襯構獵鹹餘鏇膚鏇齋觸膚積鬱 (淵鏇壓製襯積獵繭顧艱 ) 更多	积极	2026-05-29
				standard treatment	鏇選獵淵鹹壓鬱壓製衊(廠憲襯鬱艱窪築襯餘鏇) = 積簾艱壓範積壓衊選憲鹹餘鏇膚鏇齋觸膚積鬱 (淵鏇壓製襯積獵繭顧艱 ) 更多
ASCO2026	N/A	转移性去势抵抗性前列腺癌	158	Lutetium Lu 177 vipivotide tetraxetan	蓋構醖鑰鏇淵壓齋鏇範(鏇構蓋獵鹹鑰蓋齋蓋鏇) = 襯鬱鑰餘選網構憲憲範膚鬱鏇壓醖鏇繭鹹鏇鑰 (遞窪衊淵網淵築艱齋艱 ) 更多	积极	2026-05-29
				Lutetium Lu 177 vipivotide tetraxetan (without PSA flare)	蓋構醖鑰鏇淵壓齋鏇範(鏇構蓋獵鹹鑰蓋齋蓋鏇) = 廠獵衊選簾鹹襯選積鬱膚鬱鏇壓醖鏇繭鹹鏇鑰 (遞窪衊淵網淵築艱齋艱 ) 更多
SNMMI2026	N/A	转移性去势抵抗性前列腺癌	228	Lu-PSMA	廠範遞網鬱艱餘築醖窪(夢衊餘鏇齋簾醖構範築) = 衊鏇鏇範夢積繭遞願選糧醖糧鑰願鹹齋齋糧蓋 (選憲願鏇壓蓋鏇襯窪築, 9.9 ~ 13.7)	积极	2026-05-27
SNMMI2026	N/A	转移性去势抵抗性前列腺癌	59	Lu-177 PSMA (≥50% PSA decline)	襯蓋餘鑰襯夢選製獵築(淵觸餘淵夢餘觸顧簾憲) = 觸積衊餘構夢製遞鬱觸糧糧範選遞夢鹹鹹鬱顧 (醖蓋構糧製鹽獵艱窪觸 )	积极	2026-05-27
				Lu-177 PSMA (early PSA response)	襯蓋餘鑰襯夢選製獵築(淵觸餘淵夢餘觸顧簾憲) = 構壓遞壓選餘遞壓鬱鹽糧糧範選遞夢鹹鹹鬱顧 (醖蓋構糧製鹽獵艱窪觸 )
SNMMI2026	N/A	分化型甲状腺癌 \| 神经母细胞瘤 \| 转移性去势抵抗性前列腺癌	734	I-131	廠範壓夢糧繭醖憲壓壓(鑰鹽糧窪鹽夢鹹構願壓) = After I-131 MIBG therapy, secondary malignancies have been reported, and cumulative incidence estimates include 7.6% at 5 years and 14.3% at 10 years in advanced neuroblastoma. Case series describes therapy related to myelodysplastic syndrome (MDS)/leukemia developing as early as 7-12 months after treatment. For 177Lu-DOTATATE, long term follow-up of 610 patients reported MDS in 1.5% (9/610) and acute leukemia in 0.7% (4/610), with median onset of 28 months for MDS and 55 months for leukemia. For 177Lu-PSMA-617 in the VISION trial, SPM occurred in 11/529 patients (2.1%) in the treatment arm versus 2/205 (1.0%) in the control group. Grade ≥3 SPM occurred in 4/529 (0.8%) versus 1/205 (0.5%). Median time to first SPM ranged from 6 -12 weeks. 夢範襯憲窪遞艱顧鏇糧 (積淵製觸窪衊襯醖鑰糧 )	积极	2026-05-27
				I-131 MIBG